Ependymoma

Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, March 5, 2024
Glioblastoma, Breast cancer, PSTV, Rhenium, Decompression (diving), FDA, Food, GMP, PD-1, Ependymoma, Conference, Safety, Plus Therapeutics, Respect, Therapy, Food and Drug Administration, Webcast, Patient, CSF, LM, PD-L1, Pharmaceutical industry

AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent and upcoming business highlights.
  • Complete ReSPECT-LM Phase 1 dose escalation trial enrollment, determine the maximum tolerated dose, and recommended Phase 2 dose.
  • Implement Plus’ CNSide cerebral spinal fluid (CSF)-based tumor cell quantification assay as an exploratory clinical endpoint in all ReSPECT-LM trial patients in Q1 2024.
  • The Company will hold a conference call and live audio webcast at 5:00 pm Eastern Time today to discuss its financial results and provide a general business update.

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

Retrieved on: 
Monday, February 5, 2024
MYCN, Toxicity, SAN, Neoplasm, NCI, Glomus tumor, SN-38, DNA, Cmax, SLFN11, Clinical trial, Gene, Biomarker, Cell division, Patient, Safety, Irinotecan, Pros, Central nervous system, MYC, PEGylation, CNS, Phase, Medulloblastoma, TTY, Cancer, Bangladesh Technical Education Board, Ependymoma, Pharmaceutical industry

National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.

Key Points: 
  • National Institutes of Health’s NCI investigators Dr. Marta Penas-Prado and Dr. Mark Gilbert are conducting the trial.
  • High levels of MYC drive oncogenesis in many cancers and induce DNA changes leading to the formation of “topoisome complexes”.
  • The NCI trial will assess whether PLX038 is safe and efficacious in primary CNS tumors driven by MYC or MYCN amplifications.
  • For patients interested in enrolling in this clinical trial, please call NCI’s toll-free number: 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615); visit the website: https://trials.cancer.gov; and/or email: [email protected].

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

Retrieved on: 
Tuesday, January 30, 2024
Traffic barrier, Survival, NCI, Fast Track, Patient, Safety, Central nervous system, Glomus tumor, MOA, CNS, Bone marrow, Hope, SBIR, Ependymoma, Cancer, Pharmaceutical industry

“Treatment of pediatric patients with relapsed and refractory high-grade glioma and ependymoma is extremely challenging.

Key Points: 
  • “Treatment of pediatric patients with relapsed and refractory high-grade glioma and ependymoma is extremely challenging.
  • There are limited treatment options and high unmet clinical need for patients suffering from this aggressive cancer,” said Dr. Sameer Farouk Sait, pediatric hematologist-oncologist and assistant attending at Memorial Sloan Kettering Cancer Center.
  • “We understand the profound impact pediatric high-grade gliomas have on the lives of young patients and their families,” commented James Caruso, president and CEO of Cellectar.
  • We are hopeful its novel MOA will provide a meaningful treatment option for these young patients.”

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Retrieved on: 
Friday, January 5, 2024
RNA, Medical Subject Headings, Brain, Marketing, Agency, Health, INN, Risk, Stomach, Ependymoma, ATC, Medulloblastoma, Radiation, International, Blood, Language, DNA, Literature, Hodgkin lymphoma, Chemotherapy, Cancer, Skin cancer, Glioblastoma, Astrocytoma, Haematopoiesis, European Medicines Agency, Neoplasm, Transplant, Select, Cell, Patient, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Tuesday, October 31, 2023
BAM, Pakistan Society of Neuro-Oncology, FDA, Cohort, GBM, LM, Plus Therapeutics, CGMP, Rhenium, CSF, Lurie, SNO, Conference, Research, Cerebrospinal fluid, Decompression (diving), KOL, Webcast, Ependymoma, Hand, GMP, Safety, Society, Therapy, Cancer, Patient, Glioblastoma, Bangladesh Technical Education Board, Completeness, PSTV, Pharmaceutical industry, Vaccine, Internet service provider, Fine chemical, Medical imaging

AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent and upcoming business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent and upcoming business highlights.
  • Present the latest safety and efficacy data from the Phase 1 ReSPECT-LM trial at the annual SNO meeting in Vancouver on November 15-19, 2023.
  • Participate in virtual KOL webinar following SNO meeting to discuss GBM data presented at the SNO meeting.
  • The Company will hold a conference call and live audio webcast at 5:00 pm Eastern Time today to discuss its financial results and provide a general business update.

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

Retrieved on: 
Thursday, October 12, 2023
Research, Medical Devices, Clinical Trials, Radiology, University, Health, Science, Education, Oncology, Other Science, Stanford University, GBM, Ependymoma, Bevacizumab, Survival, Stanford University School of Medicine, Medicine, Cancer, Patient, Temozolomide, Stanford School, TRIDENT, Meningioma, Pharmaceutical industry, Vaccine, Medulloblastoma

Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.
  • The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
  • “We look forward to collaborating with Stanford Medicine to establish a research framework for preclinical and clinical development of TTFields,” said Moshe Giladi, Ph.D., Novocure’s Chief Science Officer.
  • At present, Stanford Medicine is a site for four clinical studies of TTFields therapy.

Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Monday, August 14, 2023
BAM, Society, Plus Therapeutics, GBM, EANM, Food and Drug Administration, SNO, Research, CNS, Bangladesh Technical Education Board, Glioblastoma, Central nervous system, ASCO, Lurie, ATM, American Society of Clinical Oncology, CGMP, Patient, Pakistan Society of Neuro-Oncology, LM, Ependymoma, PSTV, Webcast, Rhenium, FDA, Therapy, Hand, Conference, Food, Safety, Pharmaceutical industry, Fine chemical, Medical device

AUSTIN, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the second quarter ended June 30, 2023, and provided an overview of recent business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the second quarter ended June 30, 2023, and provided an overview of recent business highlights.
  • “The past 12 months have been transformative for the company,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • In the second quarter of 2023, achieved all Year 1 goals and objectives set forth in the Company’s 3-Year, $17.6M Cancer Prevention & Research Institute of Texas (CPRIT) grant.
  • Total operating expenses for the second quarter of 2023 were $3.3 million, compared to total operating expenses of $5.1 million for the same period the prior year.

Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
Thursday, April 20, 2023
BAM, Radiation, Northwestern Memorial Hospital, Completeness, Plus Therapeutics, GBM, Food and Drug Administration, Bangladesh Technical Education Board, ATM, Cancer, Patient, LM, Ependymoma, PSTV, Webcast, Rhenium, FDA, Therapy, Hand, NIH, Food, Safety, Pharmaceutical industry, Nursing, Medical device

AUSTIN, Texas, April 20, 2023 (GLOBE NEWSWIRE) --  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, April 20, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent business highlights.
  • “Our team has continued the strong momentum from 2022 through the first quarter of 2023,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.
  • The Company’s cash balance was $12.7 million at March 31, 2023, compared to $18.1 million at December 31, 2022.
  • During 2023, the Company expects to accomplish the following key business objectives:
    Publish ReSPECT-GBM Phase 1 data in a peer-reviewed journal.

Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting

Retrieved on: 
Friday, April 14, 2023
RELA, Glioma, AACR, GBM, Safety, Report, American Association for Cancer Research, Patient, SAN, Ependymoma, Section 34 of the Canadian Charter of Rights and Freedoms, Therapy, Pharmaceutical industry

SAN DIEGO, April 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its participation in the upcoming 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, Florida from April 14 through April 19, 2023, where VAL-083 data will be presented.

Key Points: 
  • SAN DIEGO, April 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced its participation in the upcoming 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place in Orlando, Florida from April 14 through April 19, 2023, where VAL-083 data will be presented.
  • Poster Section 34, Presentation Time: Monday, April 17, 2023 - 1:30 to 5:00 p.m.
  • ET
    The abstract describes two patient case reports, one with ependymoma and one with diffuse midline glioma, treated with VAL-083 under an expanded access program.
  • Safety and efficacy data will be updated at the poster presentation at the meeting.

Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Retrieved on: 
Thursday, February 23, 2023
BAM, Safety, Society, Therapy, University, Hand, SNO, Investigational New Drug, Drug development, GMP, IND, LM, Webcast, FDA, Patient, PSTV, CNS, Education, Moses Austin, CMC, Plus Therapeutics, Food and Drug Administration, Rhenium, Bangladesh Technical Education Board, GBM, Food, Ependymoma, Pharmaceutical industry, Vaccine, Cryptocurrency, Medical device

AUSTIN, Texas, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided an overview of recent business highlights.

Key Points: 
  • ET
    AUSTIN, Texas, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced financial results for the fourth quarter and year ended December 31, 2022, and provided an overview of recent business highlights.
  • Awarded $17.6 million CPRIT grant to support Phase 1 and Phase 2 clinical development of rhenium (186Re) obisbemeda for LM.
  • During the fourth quarter of 2022, the Company received its first CPRIT grant funds of approximately $1.9 million.
  • Execute corporate partnerships to expand the business opportunities for Plus Therapeutics’ unique CNS oncology platform.